These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14686996)

  • 1. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates.
    Minassian B; Huczko E; Washo T; Bonner D; Fung-Tomc J
    Clin Microbiol Infect; 2003 Dec; 9(12):1250-2. PubMed ID: 14686996
    [No Abstract]   [Full Text] [Related]  

  • 2. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN;
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
    Lewis RE; Wiederhold NP; Klepser ME
    Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.
    Castanheira M; Duncanson FP; Diekema DJ; Guarro J; Jones RN; Pfaller MA
    Antimicrob Agents Chemother; 2012 Jan; 56(1):352-7. PubMed ID: 22083469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp.
    Ortoneda M; Capilla J; Javier Pastor F; Pujol I; Guarro J
    Diagn Microbiol Infect Dis; 2004 Jan; 48(1):69-71. PubMed ID: 14761725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of four novel triazoles against Scedosporium spp.
    Carrillo AJ; Guarro J
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2151-3. PubMed ID: 11408242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of voriconazole against selected fungi.
    McGinnis MR; Pasarell L; Sutton DA; Fothergill AW; Cooper CR; Rinaldi MG
    Med Mycol; 1998 Aug; 36(4):239-42. PubMed ID: 9776841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
    Diekema DJ; Messer SA; Hollis RJ; Jones RN; Pfaller MA
    J Clin Microbiol; 2003 Aug; 41(8):3623-6. PubMed ID: 12904365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
    Johnson EM; Szekely A; Warnock DW
    J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
    Guinea J; Peláez T; Recio S; Torres-Narbona M; Bouza E
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1396-400. PubMed ID: 18212101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
    Gilgado F; Serena C; Cano J; Gené J; Guarro J
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4211-3. PubMed ID: 17015631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
    Philip A; Odabasi Z; Rodriguez J; Paetznick VL; Chen E; Rex JH; Ostrosky-Zeichner L
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
    Heyn K; Tredup A; Salvenmoser S; Müller FM
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5157-9. PubMed ID: 16304192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
    Marco F; Pfaller MA; Messer SA; Jones RN
    Med Mycol; 1998 Dec; 36(6):433-6. PubMed ID: 10206756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp.
    Venturini TP; Rossato L; Spader TB; Tronco-Alves GR; Azevedo MI; Weiler CB; Santurio JM; Alves SH
    Diagn Microbiol Infect Dis; 2011 Oct; 71(2):126-30. PubMed ID: 21840673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.
    Wildfeuer A; Seidl HP; Paule I; Haberreiter A
    Mycoses; 1998; 41(7-8):309-19. PubMed ID: 9861837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
    Espinel-Ingroff A; Johnson E; Hockey H; Troke P
    J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.
    Miyazaki M; Horii T; Hata K; Watanabe NA; Nakamoto K; Tanaka K; Shirotori S; Murai N; Inoue S; Matsukura M; Abe S; Yoshimatsu K; Asada M
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4652-8. PubMed ID: 21825291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole.
    Gómez-López A; Cuenca-Estrella M; Monzón A; Rodriguez-Tudela JL
    J Antimicrob Chemother; 2001 Dec; 48(6):919-21. PubMed ID: 11733480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.